Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + TACE in Unresectable HCC
NCT00768937Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Sep 2008
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by Medical University of Vienna. Started Sep 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00768937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768937.